<img height="1" width="1" src="https://www.facebook.com/tr?id=1582471781774081&amp;ev=PageView &amp;noscript=1">
  • Menu
  • crown-logo-symbol-1-400x551

Find it Quickly

Get Started

Select the option that best describes what you are looking for

  • Services
  • Models
  • Scientific Information

Search Here For Services

Click Here to Start Over

Search Here For Models

Click Here to Start Over

Search Here For Scientific Information

Click Here to Start Over

In Vitro

Boost oncology drug discovery with XenoBase®, featuring the largest cell line selection and exclusive 3D organoid models. Benefit from OrganoidXplore™ and OmniScreen™ for rapid, in-depth analysis.

Learn More

In Vivo

Enhance drug development with our validated in vivo models, in vitro/ex vivo assays, and in silico modeling. Tailored solutions to optimize your candidates.

Learn More

Tissue

Experience ISO-certified biobanking quality. Access top biospecimens from a global clinical network, annotated by experts for precise research.

Learn More

Biomarkers and Bioanalysis

Leverage our global labs and 150+ scientists for fast, tailored project execution. Benefit from our expertise, cutting-edge tech, and validated workflows for reliable data outcomes.

Learn More

Data Science and Bioinformatics

Harness your data and discover biomarkers with our top bioinformatics expertise. Maximize data value and gain critical insights to accelerate drug discovery and elevate projects.

Learn More

KRAS

Accelerate innovative cancer treatments with our advanced models and precise drug screening for KRAS mutations, efficiently turning insights into clinical breakthroughs.

Learn More

EGFR

Advance translational pharmacology with our diverse pre-clinical models, robust assays, and data science-driven biomarker analysis, multi-omics, and spatial biology.

Learn More

Drug Resistance

Our suite integrates preclinical solutions, bioanalytical read-outs, and multi-omics to uncover drug resistance markers and expedite discovery with our unique four-step strategy.

Learn More

Patient Tissue

Enhance treatments with our human tumor and mouse models, including xenografts and organoids, for accurate cancer biology representation.

Learn More

Bioinformatics

Apply the most appropriate in silico framework to your pharmacology data or historical datasets to elevate your study design and analysis, and to improve your chances of clinical success.

Learn More

Biomarker Analysis

Integrate advanced statistics into your drug development projects to gain significant biological insight into your therapeutic candidate, with our expert team of bioinformaticians.

Learn More

CRISPR/Cas9

Accelerate your discoveries with our reliable CRISPR solutions. Our global CRISPR licenses cover an integrated drug discovery platform for in vitro and in vivo efficacy studies.

Learn More

Genomics

Rely on our experienced genomics services to deliver high quality, interpretable results using highly sensitive PCR-based, real-time PCR, and NGS technologies and advanced data analytics.

Learn More

In Vitro High Content Imaging

Gain more insights into tumor growth and disease progression by leveraging our 2D and 3D fluorescence optical imaging.

Learn More

Mass Spectrometry-based Proteomics

Next-generation ion mobility mass spectrometry (MS)-based proteomics services available globally to help meet your study needs.

Learn More

Ex Vivo Patient Tissue

Gain better insight into the phenotypic response of your therapeutic candidate in organoids and ex vivo patient tissue.

Learn More

Spatial Multi-Omics Analysis

Certified CRO services with NanoString GeoMx Digital Spatial Profiling.

Learn More

Biomarker Discovery

De-risk your drug development with early identification of candidate biomarkers and utilize our biomarker discovery services to optimize clinical trial design.

Learn More

DMPK Services

Rapidly evaluate your molecule’s pharmaceutical and safety properties with our in vivo drug metabolism and pharmacokinetic (DMPK) services to select the most robust drug formulations.

Learn More

Efficacy Testing

Explore how the novel HuGEMM™ and HuCELL™ platforms can assess the efficacy of your molecule and accelerate your immuno-oncology drug discovery programs.

Learn More

Laboratory Services

Employ cutting-edge multi-omics methods to obtain accurate and comprehensive data for optimal data-based decisions.

Learn More

Pharmacology & Bioanalytical Services

Leverage our suite of structural biology services including, recombinant protein expression and protein crystallography, and target validation services including RNAi.

Learn More

Screens

Find the most appropriate screen to accelerate your drug development: discover in vivo screens with MuScreen™ and in vitro cell line screening with OmniScreen™.

Learn More

Toxicology

Carry out safety pharmacology studies as standalone assessments or embedded within our overall toxicological profiling to assess cardiovascular, metabolic and renal/urinary systems.

Learn More

Our Company

Global CRO in California, USA offering preclinical and translational oncology platforms with high-quality in vivo, in vitro, and ex vivo models.

Learn More

Our Purpose

Learn more about the impact we make through our scientific talent, high-quality standards, and innovation.

Learn More

Our Responsibility

We build a sustainable future by supporting employee growth, fostering leadership, and exceeding customer needs. Our values focus on innovation, social responsibility, and community well-being.

Learn More

Meet Our Leadership Team

We build a sustainable future by fostering leadership, employee growth, and exceeding customer needs with innovation and social responsibility.

Learn More

Scientific Advisory Board

Our Scientific Advisory Board of experts shapes our strategy and ensures top scientific standards in research and development.

Learn More

News & Events

Stay updated with Crown Bioscience's latest news, achievements, and announcements. Check our schedule for upcoming events and plan your visit.

Learn More

Career Opportunities

Join us for a fast-paced career addressing life science needs with innovative technologies. Thrive in a respectful, growth-focused environment.

Learn More

Scientific Publications

Access our latest scientific research and peer-reviewed articles. Discover cutting-edge findings and insights driving innovation and excellence in bioscience.

Learn More

Resources

Discover valuable insights and curated materials to support your R&D efforts. Explore the latest trends, innovations, and expertly curated content in bioscience.

Learn More

Blogs

Explore our blogs for the latest insights, research breakthroughs, and industry trends. Stay educated with expert perspectives and in-depth articles driving innovation in bioscience.

Learn More

  • Platforms
  • Target Solutions
  • Technologies
  • Service Types

Preclinical Biomarker Discovery: Top 17 Questions

Review key questions on preclinical biomarker discovery from our recent webinar, answered by Mike Batey.Review key questions on preclinical biomarker discovery from our recent webinar, answered by Mike Batey.

Biomarker Identification from In Vitro Screens

For In Vitro Screens – Are Cell Lines Patient Derived, and Do You Correlate with Patient-Derived Cells?

The cell lines typically used are those common to cancer therapeutic testing, and available from providers such as the ATCC. We can also use cells taken from patient-derived xenograft (PDX) models in vitro. PDX are derived from patient tissue and propagated in mice, and are therefore closer to the clinical situation.

We’ve also recently launched an organoid platform which can be used for initial screening, including organoids derived from PDX and directly from clinical patient material. This provides a translational bridge from in vitro screening to in vivo testing.

How Likely is it That a Biomarker Discovered in the In Vitro Stage is Translated to the Clinic?

The discovery of a biomarker with clinical utility is feasible at the preclinical stage, by using PDX in both in vivo and in vitro experimental systems. The key factors for success are:

  1. Commitment to biomarker discovery at an early stage
  2. Access to a wide number/range of PDX, with available molecular characterization and which replicates clinical diversity
  3. Appropriate selection of PDX models based on molecular data and/or a biomarker hypothesis generated using in vitro data

Using Translational PDX Models and Mouse Clinical Trials in Biomarker Discovery

How Valuable do you Feel Data from a Single PDX Model Are?

Individual PDX models with particular genetic profiles can be very informative on drug mechanism of action. For mouse clinical trials, several different PDX models are run and it is the result from the whole clustered study rather than individual PDX which holds most value.

How Many PDX Models or Cell Lines do we Need to Use to get a Meaningful Result?

This can depend on a number of factors including the question being asked, however we have in the past ran successful studies using 30-40 cell lines, and as few as 21 PDX models.

What is the Ideal Number of Mice/Group in an MCT?

This varies from study to study but typically we would use 2/3 mice per group. Our published MCT paper goes into a lot of detail as to the appropriate design and use of MCTs.

Is the Broadness in PDX Models Good Enough to use the Outcome for Patient Selection/Stratification. For Instance, Genetic Heterogeneity in AML is High. Is that Appropriately Represented in AML PDX Models you Have at CrownBio?

This depends on the disease type. For several cancers, such as colorectal, we have a large number of models available. For AML, we only have a limited number of models which may not fully reflect patient heterogeneity.

Where are Your PDX Models from for MCTs?

From the CrownBio PDX bank, which can be easily searched online to review the wide model collection available.

Are your Tumor Volumes Analyzed by Personnel Blind to Treatment? What are Groups Sizes for your In Vivo Models (Power, Effect Size)?

We do have the ability to run our tumor models blind to treatment group and independent of dosing. Group sizes for in vivo studies vary according to the question being asked, the robustness of the model being run, and the power required. For a typical PDX we can go as low as 3 animals per group, with the typical range being 5-8.

How do you Test Resistance for Drugs?

Typically, a PDX model (or cell line) will be exposed to a relevant concentration of drug on a relevant dosing regimen, and response measured.

New Strategies to Overcome Challenges in Biomarker Discovery

Discovery, Development, Validation, up to Implementation of Biomarkers in Clinical Settings is Long and Complex. What New Strategies and Applications Exist to Adopt more Biomarker-Driven Clinical Trials?

Our platform can support drug discovery and development right from the in silico stage, through in vitro and in vivo, and with our sister company MBL, take a discovered biomarker right through to the clinic. This is a complex process, but with in-house expertise you can be supported through every step.

What is the Most Challenging Task when you Take Biomarkers for Clinical Evaluation?

Translating a preclinical biomarker into the clinical space comes with multiple challenges. Key to making this as smooth a process as possible is being mindful of the intended usage of your biomarker in clinic, and ensuring that the biomarkers you choose in the preclinical space for further development have clinical relevance.

Operational Questions in Biomarker Discovery

If We Do Not Want to Disclose the Drug Identity and Target, can you still Perform Biomarker Discovery?

Yes, we can, and have several examples where we have done this in the past for customers (one of which is included within our webinar). This utilizes hypothesis-free biomarker discovery which can be performed without any knowledge of the drug or mechanism of action, and is not limited by patient heterogeneity.

Do we Have to Conduct Lab Work, or can we use Historical Data, or Data from Other Providers?

We are happy to take raw data from other providers, or historical data to perform biomarker discovery.

Can we Retrospectively look at Clinical Data to Identify a Biomarker?

Yes, this is perfectly possible. We can also then advise and perform appropriate preclinical studies to validate that biomarker for further clinical use.

When you Discover a Biomarker for a Client, Whose Intellectual Property is it?

This depends on how the client study and contract are set up, and how the customer wants to work with us. Options include customer retaining all i.p. or in certain instances we may share i.p. depending on how clients want to collaborate with our team.

If we Run these Studies with CrownBio, do they have to be Performed in China?

No - we have sites in both North America and in Europe where studies can be conducted. Some models are run in specific geographies, but we can advise as to what would be most appropriate.

Have you Tried to Identify Anti-PD-1 Response Biomarkers?

Yes, we can and have achieved this.

Contact us with any further questions on our biomarker discovery capabilities.


Related Posts